Navigation Links
Moffitt Cancer Center researchers design small molecule to disrupt cancer-causing protein
Date:3/25/2013

Researchers at Moffitt Cancer Center and colleagues at the University of South Florida have developed a small molecule that inhibits STAT3, a protein that causes cancer. This development could impact the treatment of several tumor types, including breast, lung, prostate and others that depend on STAT3 for survival.

The study appeared in the Jan. 15 online issue of Cancer Research, a publication of the American Association for Cancer Research.

"STAT3 has been associated with poor prognosis and resistance to chemotherapy in patients with cancer," explained Said M. Sebti, Ph.D., chair of the Drug Discovery Department at Moffitt. "Two STAT3 molecules need to bind to each other, a process called dimerization, to cause malignancy. We developed a small molecule called S3I-1757 to prevent dimerization by disrupting STAT3-STAT3 binding. Once disrupted, STAT3's ability to help cancer cells survive, grow and invade is neutralized."

"Activated STAT3 contributes to cancer at several levels," said study co-author Nicholas J. Lawrence, Ph.D., senior member of Moffitt's Drug Discovery Department. "It triggers the uncontrolled proliferation, invasion and spread of cancer cells. That makes STAT3 an attractive target for drug discovery and therapy."

STAT3 was first found to be involved in malignant transformation in 1995, but researchers have been unable to develop an inhibitor for the protein. In part, the challenge stemmed from the fact that STAT3-STAT3 binding is a protein-protein interaction involving a large surface area, difficult to target with drug-like small molecules.

The researchers, who had been working on finding an inhibitor for STAT3-STAT3 dimerization for some time, recently overcame that challenge and demonstrated in laboratory studies that S31-1757 was effective in neutralizing STAT3's activity.

"We used several approaches to demonstrate that S31-1757 is able to inhibit malignant transformation by its ability to inhibit the STAT3 function," Sebti said. "These included targeting the ability of STAT3 to bind itself."

Their findings will be presented at the annual AACR meeting in April in Washington, D.C.


'/>"/>

Contact: Kim Polacek
kim.polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Genetic risk strategies needed for young, black, female breast cancer patients, Moffitt study shows
2. Moffitt Cancer Center researchers study use of dasatinib for patients with high-risk MDS
3. Cancer doesnt change young girls desire to have children, Moffitt Cancer Center study shows
4. Surgery and radiation improve survival for metastatic gastric cancer patients, Moffitt study shows
5. Moffitt researchers say silencing of retinoblastoma gene regulates differentiation of myeloid cells
6. Moffitt researchers find potential new therapeutic target for treating non-small cell lung cancer
7. Moffitt Cancer Center researchers develop automated breast density test linked to cancer risk
8. Tumor cells engineer acidity to drive cell invasion, Moffitt Cancer Center researchers say
9. New drug improves survival in multiple myeloma relapse, Moffitt Cancer Center researchers say
10. Moffitt study shows smoking cessation more successful for cancer patients who quit before surgery
11. Hispanics leery of health care providers, often avoid cancer screenings, Moffitt study shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... 2017 , ... In its just released 2018 Edition, The Best Lawyers in ... the third consecutive year that Hardiman and Mills have been honored and the seventh ... in Health Care Law while Mills was recognized in the Administrative and Regulatory Law ...
(Date:8/17/2017)... ... August 17, 2017 , ... SeQuel Response announced today that for ... among the fastest-growing private companies in the U.S., putting it in the top 10 ... applied to the Inc. 5000 over the years, only a fraction have ...
(Date:8/17/2017)... ... August 17, 2017 , ... An August 2 article on NextShark ... surgery, largely influenced by the growing popularity of “pretty boys” in both K-Pop and ... standards of male appearance are changing not only in the Asian nation, where plastic ...
(Date:8/17/2017)... Mesa, CO (PRWEB) , ... August 17, 2017 ... ... & Moral Injury: The Journey to Healing Through Forgiveness ($15.99, paperback, 9781498497626; ... disorder (war) trauma, to encourage inner healing of memories and achieve forgiveness, through ...
(Date:8/17/2017)... ... 17, 2017 , ... Inc. Magazine Unveils 36th Annual List of America’s Fastest-Growing ... Growth of 3,004.8% , NEW YORK, August 16, 2017 – Inc. magazine today ranked ... of the nation's fastest-growing private companies. The list represents a unique look at the ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... Fenita J. Caldwell is ... Lifetime Professional in the Field of Healthcare. Caldwell ... Pharmaceuticals, AG. Her skills and areas of expertise ... Fenita ... experience as a highly successful sales specialist in ...
(Date:8/1/2017)... , Aug. 1, 2017   CerSci Therapeutics , ... Dallas, Texas , has received notice from the ... Institutes of Health (NIH) that it has been awarded ... totaling over $650,000 in 2017 with an additional $1,000,000 ... Investigational New Drug application of their lead non-opioid drug ...
(Date:7/28/2017)... Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today announced financial ... 2017, and updated its financial outlook for fiscal 2017. ... fiscal third quarter, Hill-Rom reported earnings of $0.09 per ... the prior-year period. These results reflect after-tax special items, ... related to the non-cash write-down of assets associated with ...
Breaking Medicine Technology: